The European Medicines Agency will review drugs similar to Vioxx after its withdrawal by Merck due to increased stroke and heart attack risks.
Vioxx, a COX-2 inhibitor, generated $2.5 billion in sales in 2003.
Pfizer's Bextra and Celebrex are also under scrutiny.
Lawsuits have been filed against Merck for withholding information on Vioxx's risks.
Studies show Vioxx's link to heart issues, impacting Merck's earnings.
The company faces legal challenges and criticism for not addressing Vioxx's dangers earlier.
The Vioxx recall may lead to more lawsuits and a re
